Participated · Series D · Aug 2026

Hopscotch Primary Care operates a technology-enabled primary care model serving rural communities across the southeastern United States. Founded in 2021, the company serves more than 15,000 patients through 12 clinical locations, with its largest concentration in rural Western North Carolina. Its model emphasizes same-day visits, 24/7 access to care teams, and proactive outreach supported by administrative and clinical technology. Hopscotch reports strong patient-facing metrics—Net Promoter Score of 89 and patient retention above 90%—and says it has driven medical-loss-ratio improvement of over 25 percentage points for patients in their first two years. That operating performance is already translating to profitable operations in Western North Carolina. The company plans to use recent funding to expand into additional rural markets and continue scaling its technology-powered operations.

Participated · Series B · Jun 2026

Connie Health is an AI-native Medicare navigation platform that combines proprietary technology with a network of local trusted agents to help seniors find and enroll in appropriate Medicare coverage. The company powers agent workflows and consumer guidance with AI and intelligent automation and positions itself as a strategic partner to Accountable Care Organizations, health systems, and risk-bearing providers. Connie recently completed its 10th acquisition, integrating Clearlink's Medicare business, and announced a $40 million Series B, bringing total funding to date to $85 million. It plans to use capital to expand its agent network, pursue additional M&A, advance its AI-driven platform, and deepen integrations with value-based care partners. Connie is headquartered in Boston and emphasizes preserving local, human-centered support while scaling through technology.

Led · Equity · Jan 2026

KAHR Bio is a clinical-stage biotechnology company based in Modi’in, Israel that creates dual-targeting fusion protein therapeutics designed to activate both the innate and adaptive immune systems within the tumor microenvironment. Its lead candidate, DSP107, is a first-in-class bispecific CD47×4-1BB T-cell engager that anchors to CD47-expressing tumor cells while delivering a potent 4-1BB co-stimulatory signal to recruit and activate cytotoxic T cells. Across more than 130 treated patients, DSP107 has shown a favorable safety and tolerability profile. In a Phase 2a study of heavily pre-treated metastatic microsatellite stable colorectal cancer (MSS-CRC), DSP107 combined with atezolizumab achieved a 17.5-month median overall survival, outperforming the 6.4–10.8 months generally seen with approved therapies, even though 75% of patients had liver metastases. Encouraged by these data, the company has launched a randomized, controlled Phase 2b trial comparing DSP107 plus atezolizumab to fruquintinib in fourth-line MSS-CRC, with interim results expected in late 2026 and topline data in the second half of 2027. Proceeds from its latest financing and an accompanying debt facility are intended to fully fund this Phase 2b program and other R&D activities.

Participated · Series A · Dec 2025

Founded in 2021, Denver-based Lin Health offers a physician-led, coach-supported virtual program that retrains maladaptive pain circuits through therapies such as Pain Reprocessing Therapy, Emotional Awareness and Expression Therapy, and Cognitive Behavioral Therapy. The platform combines proprietary software, AI, and a collaborative care model to engage patients multiple times per week without adding administrative burden. Lin partners with health systems, clinics, and payers and is already accessible to more than 60 million covered Americans. Its solution targets chronic conditions including migraines, IBS, back pain, and joint pain, addressing a $635 billion annual cost burden in the U.S. healthcare system. The company emphasizes value-based outcomes, reduced provider burnout, and lower total cost of care. With fresh Series A capital, Lin plans to accelerate product innovation, scale go-to-market efforts, and deepen clinically integrated partnerships. The oversubscribed funding signals strong investor confidence in Lin’s ability to become the first-line solution for chronic pain nationwide.

Participated · Series A · Oct 2025

Adcytherix focuses on designing and developing highly selective antibody-drug conjugates that incorporate proprietary payloads aimed at improving efficacy, tolerability, and resistance profiles in oncology. Its lead candidate, ADCX-020, is progressing toward first-in-human studies, with IND and CTA filings targeted for the end of 2025. In parallel, the company is expanding a broader pipeline of differentiated ADCs that leverage its novel payload platform. Founded about 18 months ago and led by CEO and founder Jack Elands, the team draws on deep scientific and commercial expertise in the ADC field. The company positions itself as a European leader in next-generation ADC innovation, emphasizing precision targeting and payload differentiation. With the recent €105 million Series A financing, Adcytherix now has substantial resources to transition from preclinical research to clinical development. The new capital underpins both the advancement of ADCX-020 and the ongoing build-out of its proprietary ADC platform.